Top

BMC Immunology

Published in:

Open Access 01-12-2021 | Obesity | Research article

Serum IL-35 is decreased in overweight patients with rheumatoid arthritis: its correlation with Th1/Th2/Th17-related cytokines

Authors: Yuxuan Li, Yang Jie, Xiaofei Wang, Jing Lu

Published in: BMC Immunology | Issue 1/2021

Abstract

Background

Obesity is correlated with worse drug responses and high disease activity in patients with rheumatoid arthritis (RA). Interleukin (IL)-35 is a novel anti-inflammatory cytokine that mainly produced by regulatory T (Treg). This study was performed to analyze whether IL-35 was correlated with obesity in RA and investigate the correlation between other Th1/Th2/Th17-related cytokines and obesity in RA.

Results

The serum IL-35 level was analyzed in RA (n = 81) and healthy donors (n = 53) by ELISA assay, and was compared between three groups (body mass index (BMI) < 18.5,≥18.5 to 25, > 25). Serum cytokines including IL-2, IL-4, IL-10, IL-17, INF-γ, TNF-α levels were measured using Flowcytometry assay. Clinical information was extracted from medical records. Serum IL-35 level in overweight patients were significantly decreased than those in lean patients. Furthermore, Th1/Th2/Th17-related cytokines from overweight patients with RA showed the characteristic immunological features. Serum IL-6, IL-17 and TNF-α levels were positively correlated with BMI. However, serum IL-2, IL-4, IL-10 and IFN-γ concentrations were not correlated with BMI.

Conclusions

Quantitative changes in serum IL-35 level were characteristic in overweight patients with RA. These findings indicate that IL-35 plays an important role in the development of RA and may prove to be a potential biomarker of active RA.

Available only for authorised users

Klaasen R, Wijbrandts CA, Gerlag DM, Tak PP. Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011;63(2):359–64. https://doi.org/10.1002/art.30136.CrossRefPubMed

Gremese E, Carletto A, Padovan M, Atzeni F, Raffeiner B, Giardina AR, et al. Obesity and reduction of the response rate to anti-tumor necrosis factor alpha in rheumatoid arthritis: an approach to a personalized medicine. Arthritis Care Res. 2013;65(1):94–100. https://doi.org/10.1002/acr.21768.CrossRef

Sandberg ME, Bengtsson C, Källberg H, Wesley A, Klareskog L, Alfredsson L, et al. Overweight decreases the chance of achieving good response and low disease activity in early rheumatoid arthritis. Ann Rheum Dis. 2014;73(11):2029–33. https://doi.org/10.1136/annrheumdis-2013-205094.CrossRefPubMed

Ajeganova S, Andersson ML, Hafstrom I. Association of obesity with worse disease severity in rheumatoid arthritis as well as with comorbidities: a long-term followup from disease onset. Arthritis Care Res. 2013;65(1):78–87. https://doi.org/10.1002/acr.21710.CrossRef

Bluher M. Adipose tissue inflammation: a cause or consequence of obesity-related insulin resistance? Clinical science (London, England : 1979). 2016;130(18):1603–14.CrossRef

Fantuzzi G. Adiponectin in inflammatory and immune-mediated diseases. Cytokine. 2013;64(1):1–10. https://doi.org/10.1016/j.cyto.2013.06.317.CrossRefPubMedPubMedCentral

Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115(5):911–9; quiz 920. https://doi.org/10.1016/j.jaci.2005.02.023.CrossRefPubMed

Catalan-Dibene J, McIntyre LL, Zlotnik A. Interleukin 30 to Interleukin 40. J Interferon Cytokine Res. 2018;38(10):423–39. https://doi.org/10.1089/jir.2018.0089.CrossRefPubMedPubMedCentral

Collison LW, Vignali DA. Interleukin-35: odd one out or part of the family? Immunol Rev. 2008;226(1):248–62. https://doi.org/10.1111/j.1600-065X.2008.00704.x.CrossRefPubMedPubMedCentral

10.

Yokota M, Suzuki M, Nakamura Y, Ozaki S, Murakami S. Cytokine modulation by IL-35 in mice with allergic rhinitis. Am J Rhinol Allergy. 2015;29(4):251–6. https://doi.org/10.2500/ajra.2015.29.4188.CrossRefPubMed

11.

Bettini M, Castellaw AH, Lennon GP, Burton AR, Vignali DA. Prevention of autoimmune diabetes by ectopic pancreatic β-cell expression of interleukin-35. Diabetes. 2012;61(6):1519–26. https://doi.org/10.2337/db11-0784.CrossRefPubMedPubMedCentral

12.

Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14(1):397–440. https://doi.org/10.1146/annurev.immunol.14.1.397.CrossRefPubMed

13.

McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol. 2007;7(6):429–42. https://doi.org/10.1038/nri2094.CrossRef

14.

Burska A, Boissinot M, Ponchel F. Cytokines as biomarkers in rheumatoid arthritis. Mediat Inflamm. 2014;2014:545493.

15.

Charlton B, Lafferty KJ. The Th1/Th2 balance in autoimmunity. Curr Opin Immunol. 1995;7(6):793–8. https://doi.org/10.1016/0952-7915(95)80050-6.CrossRefPubMed

16.

Aarvak T, Chabaud M, Thoen J, Miossec P, Natvig JB. Changes in the Th1 or Th2 cytokine dominance in the synovium of rheumatoid arthritis (RA): a kinetic study of the Th subsets in one unusual RA patient. Rheumatology (Oxford). 2000;39(5):513–22. https://doi.org/10.1093/rheumatology/39.5.513.CrossRef

17.

Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132(6):2169–80. https://doi.org/10.1053/j.gastro.2007.03.059.CrossRefPubMed

18.

Finckh A, Turesson C. The impact of obesity on the development and progression of rheumatoid arthritis. Ann Rheum Dis. 2014;73(11):1911–3. https://doi.org/10.1136/annrheumdis-2014-205741.CrossRefPubMed

19.

Ning X, Jian Z, Wang W. Low serum levels of interleukin 35 in patients with rheumatoid arthritis. Tohoku J Exp Med. 2015;237(2):77–82. https://doi.org/10.1620/tjem.237.77.CrossRefPubMed

20.

Collison LW, Chaturvedi V, Henderson AL, Giacomin PR, Guy C, Bankoti J, et al. IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol. 2010;11(12):1093–101. https://doi.org/10.1038/ni.1952.CrossRefPubMedPubMedCentral

21.

Niedbala W, Wei XQ, Cai B, Hueber AJ, Leung BP, McInnes IB, et al. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol. 2007;37(11):3021–9. https://doi.org/10.1002/eji.200737810.CrossRefPubMed

22.

Li Y, Yao L, Liu S, Wu J, Xia L, Shen H, et al. Elevated serum IL-35 levels in rheumatoid arthritis are associated with disease activity. J Investigative Med. 2019;67(3):707–10. https://doi.org/10.1136/jim-2018-000814.CrossRef

23.

Li Y, Yuan L, Yang J, Lei Y, Zhang H, Xia L, et al. Changes in serum cytokines may predict therapeutic efficacy of Tofacitinib in rheumatoid arthritis. Mediat Inflamm. 2019;2019:5617431.

24.

Shoda H, Nagafuchi Y, Tsuchida Y, Sakurai K, Sumitomo S, Fujio K, et al. Increased serum concentrations of IL-1 beta, IL-21 and Th17 cells in overweight patients with rheumatoid arthritis. Arthritis Res Therapy. 2017;19(1):111. https://doi.org/10.1186/s13075-017-1308-y.CrossRef

25.

Feuerer M, Herrero L, Cipolletta D, Naaz A, Wong J, Nayer A, et al. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. 2009;15(8):930–9. https://doi.org/10.1038/nm.2002.CrossRefPubMedPubMedCentral

26.

Sindhu S, Thomas R, Shihab P, Sriraman D, Behbehani K, Ahmad R. Obesity is a positive modulator of IL-6R and IL-6 expression in the subcutaneous adipose tissue: significance for metabolic inflammation. PLoS One. 2015;10(7):e0133494. https://doi.org/10.1371/journal.pone.0133494.CrossRefPubMedPubMedCentral

27.

Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, et al. Obesity predisposes to Th17 bias. Eur J Immunol. 2009;39(9):2629–35. https://doi.org/10.1002/eji.200838893.CrossRefPubMed

28.

Jhun JY, Yoon BY, Park MK, Oh HJ, Byun JK, Lee SY, et al. Obesity aggravates the joint inflammation in a collagen-induced arthritis model through deviation to Th17 differentiation. Exp Mol Med. 2012;44(7):424–31. https://doi.org/10.3858/emm.2012.44.7.047.CrossRefPubMedPubMedCentral

29.

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–81.CrossRef

Title: Serum IL-35 is decreased in overweight patients with rheumatoid arthritis: its correlation with Th1/Th2/Th17-related cytokines
Authors: Yuxuan Li
Yang Jie
Xiaofei Wang
Jing Lu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Obesity
Obesity
Rheumatoid Arthritis
Cytokines
Overweight
Published in: BMC Immunology / Issue 1/2021
Electronic ISSN: 1471-2172
DOI: https://doi.org/10.1186/s12865-021-00431-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study

Type 2 and type 3 innate lymphoid cells at the maternal-fetal interface: implications in preterm birth

Naïve CD4+ cell counts significantly decay and high HIV RNA levels contribute to immunological progression in long-term non-progressors infected with HIV by blood products: a cohort study

Clinical observations of bone marrow transfusion for promoting bone marrow reconstruction after chemotherapy for AIDS-related lymphoma

Differential long non-coding RNA expression profile and function analysis in primary Sjogren’s syndrome

Intratumoral regulatory T cells from colon cancer patients comprise several activated effector populations

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials